ORGANIZATION
    PhRMA Taps Jonathan Kushner as New Japan Representative
    October 6, 2026
    The Pharmaceutical Research and Manufacturers of America (PhRMA) said on October 6 that it has named Jonathan Kushner as its new Japan representative, succeeding Hans Klemm.Kushner most recently headed corporate relations at McDonald’s Japan, where…

    LATEST

    LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
    October 6, 2026
    Japanese startup LinDo is looking to expand its product lineup with a focus on pediatric medicines, with in-licensing talks already underway for its second and third assets, President and CEO Jun Katsura told Jiho.The company’s…
    Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
    October 6, 2026
    Shionogi said on October 5 that it will acquire US biotech IntraBio for US$2 billion, gaining Aqneursa (levacetylleucine), an approved treatment for genetic neurodegenerative conditions, as it steps up its push into rare diseases.The Osaka…
    Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
    October 6, 2026
    Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for new manufacturing capacity, seeking to reverse a sharp decline in the country’s self-sufficiency in immunoglobulin…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COLUMN

    Outside the Bubble: Lunch with Pharma Delegates
    By Philip Carrigan

    The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

    COMMENTARY

    Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
    By Shinya Sato

    The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA